Livagen 20 mg

Livagen 20 mg contains the KEDA tetrapeptide, a synthetic peptide bioregulator studied for its proposed interaction with hepatocyte DNA and effects on liver gene expression. No human clinical trials have evaluated Livagen for any indication, and all use outside research applications falls outside approved indications.

Community protocols commonly reference Livagen being administered daily for 10–20 day cycles, followed by extended breaks of several months. Doses in these protocols range from 10 mg to 20 mg per administration. These figures are anecdotal and not medically established, as no human trial has established a safe or effective dose.

No. Livagen acts on hepatocyte gene expression and chromatin remodeling rather than the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production, so post-cycle therapy in the context of testosterone recovery is not applicable. A break between cycles is commonly referenced in community protocols to allow chromatin changes and gene expression effects to take hold.

Livagen is proposed to interact with DNA regulatory sequences in hepatocytes, causing chromatin decondensation and increased transcription of genes involved in liver function, detoxification, and regeneration. Animal studies have reported increased protein synthesis in cultured hepatocytes and modulation of digestive enzyme activity. The specific molecular targets and mechanisms have not been independently validated.

The time course for Livagen is not established in humans. Published animal research describes effects on protein synthesis and enzyme activity developing over the course of administration, with two-week treatment periods used in rat studies. Community protocols typically reference 10–20 day cycles, with benefits proposed to persist after the cycle ends due to epigenetic changes.

There is no evidence-based “best” liver-support peptide. Livagen is proposed to act through hepatocyte gene regulation, while Glutathione provides antioxidant support through a different mechanism. The appropriate approach depends on individual goals and circumstances, and all non-medical use falls outside approved indications.

Both are synthetic tetrapeptide bioregulators developed by Vladimir Khavinson, but they target different tissues. Livagen (Lys-Glu-Asp-Ala) is studied for liver tissue, while Ovagen is investigated for different organ-specific effects. The two peptides have distinct amino acid sequences and proposed tissue targets.

Livagen (Lys-Glu-Asp-Ala) is studied for liver tissue, while Epitalon (Ala-Glu-Asp-Gly) is investigated for pineal gland effects and telomerase activation. Both are Khavinson bioregulator peptides with tissue-specific effects, but they have different amino acid sequences and research applications.

The 20 mg vial strength provides flexibility for reconstitution and dosing. Community protocols commonly reference 10–20 mg per administration, so a single 20 mg vial would provide one to two doses depending on the protocol. Because dosing is not clinically established, the appropriate amount should be based on research context rather than a fixed protocol.

Livagen 20 mg is labeled at 20 mg of Livagen (KEDA tetrapeptide) per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized Livagen is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Because reported amounts are small, mixing the powder correctly matters more than usual, and a misread on the syringe can swing the actual dose several-fold. Proper sterile technique should be used during reconstitution.